Share
Scientists at the Helmholtz Zentrum München have examined health insurance data of more than 300,000 people with diabetes in Germany. Their report, published in Diabetes Care, breaks down the costs involved in treating various complications of the disease. The Helmholtz authors are members of the German Center for Diabetes Research (DZD). It is estimated that...
Share
Eli Lilly and Company and Livongo Health today announced a strategic collaboration to study real-world evidence and develop new insights to reduce the burden on people living with diabetes. The research collaboration will combine real-world behavioral studies and claims data to advance knowledge about effective interventions in diabetes care. The companies aim to contribute to...
Share
Lipid nanodiscs stabilize misfolding protein intermediates red-handed When proteins misfold, accumulate, and clump in insulin-producing cells in the pancreas, they can kill these cells. Now, researchers at the Technical University of Munich (TUM), the University of Michigan, and the Helmholtz-Zentrum Muenchen have obtained a structural snapshot of these proteins when they are most toxic, detailing...
Share
Researchers in Norway have found very little incidence of end-stage renal disease (ESRD) among those with childhood-onset type 1 diabetes who were followed for up to 42 years, according to a study recently published in Diabetes Care. Researchers led by Torild Skrivarhaug, PhD, of Oslo University Hospital, evaluated patient data for a follow-up period of...
Share
Researchers in South Africa have shown that regularly drinking sugar-sweetened beverages (SSBs) contributes to the development of diabetes, high blood pressure, metabolic syndrome, and other endemic health problems, according to a review recently published in the Journal of the Endocrine Society. The review’s authors, led by M. Faadiel Essop, PhD, of Stellenbosch University in Stellenbosch,...
Share
The U.S. Food and Drug Administration (FDA) approved semaglutidea once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The drug, produced by Novo Nordisk and marketed as OZEMPIC®, is administered once weekly, on the same day each week, and can be taken...
Share
The Society hosted a Diabetes Awareness Month Twitter chat on Nov. 9 to raise awareness of the dangers of hypoglycemia. Twitter users saw the event hashtag, #EndoChat, an estimated 1.2 million times in the days leading up to the discussion and during the chat itself, according to the social media analytics firm Symplur. The event...
Share
Researchers are still looking forwhat sets off the autoimmune response that causes type 1 diabetes, and one of the leading theories is that a virus is the culprit. In a study recently published in the Journal of the Endocrine Society, a team of investigators looked at how infecting human islets with the enterovirus coxsackievirus B4...
